BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35501218)

  • 1. Impact of spatio-temporal recurrence pattern on overall survival for invasive intraductal papillary mucinous neoplasia - A comparison with pancreatic ductal adenocarcinoma.
    Holmberg M; Linder S; Kordes M; Liljefors M; Ghorbani P; Löhr JM; Sparrelid E
    Pancreatology; 2022 Jun; 22(5):598-607. PubMed ID: 35501218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome after surgery for invasive intraductal papillary mucinous neoplasia compared to conventional pancreatic ductal adenocarcinoma - A Swedish nationwide register-based study.
    Holmberg M; Radkiewicz C; Strömberg C; Öman M; Ghorbani P; Löhr JM; Sparrelid E
    Pancreatology; 2023 Jan; 23(1):90-97. PubMed ID: 36522260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome after resection for invasive intraductal papillary mucinous neoplasia is similar to conventional pancreatic ductal adenocarcinoma.
    Holmberg M; Ghorbani P; Gilg S; Del Chiaro M; Arnelo U; Löhr JM; Sparrelid E
    Pancreatology; 2021 Oct; 21(7):1371-1377. PubMed ID: 34426077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of para-aortic lymph node status in resected pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous neoplasm - Time to consider a reclassification?
    Linder S; Holmberg M; Engstrand J; Ghorbani P; Sparrelid E
    Surg Oncol; 2022 May; 41():101735. PubMed ID: 35287096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN.
    Kang MJ; Lee KB; Jang JY; Kwon W; Park JW; Chang YR; Kim SW
    Pancreas; 2013 Nov; 42(8):1267-74. PubMed ID: 24308063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of Neoadjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Neoplasm Compared with de Novo Pancreatic Adenocarcinoma.
    Fogliati A; Zironda A; Fiorentini G; Adjei S; Amro A; Starlinger PP; Grotz TE; Warner SG; Smoot RL; Thiels CA; Kendrick ML; Cleary SP; Truty MJ
    Ann Surg Oncol; 2024 Apr; 31(4):2632-2639. PubMed ID: 38319513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invasive IPMN relapse later and more often in lungs in comparison to pancreatic ductal adenocarcinoma.
    Capretti G; Nebbia M; Gavazzi F; Nappo G; Ridolfi C; Sollai M; Spaggiari P; Bozzarelli S; Carrara S; Luberto A; Zerbi A
    Pancreatology; 2022 Sep; 22(6):782-788. PubMed ID: 35701318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival after resection for invasive intraductal papillary mucinous neoplasm and for pancreatic adenocarcinoma: a multi-institutional comparison according to American Joint Committee on Cancer Stage.
    Waters JA; Schnelldorfer T; Aguilar-Saavedra JR; Chen JH; Yiannoutsos CT; Lillemoe KD; Farnell MB; Sarr MG; Schmidt CM
    J Am Coll Surg; 2011 Aug; 213(2):275-83. PubMed ID: 21601488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-emptive resection for intraductal papillary mucinous neoplasia - Long-term outcome is similar between non-invasive and early invasive lesions in a tertiary single center.
    Djoumi Y; Sadr-Azodi O; Vujasinovic M; Del Chiaro M; Sparrelid E; Ghorbani P; Holmberg M
    Pancreatology; 2023 Jun; 23(4):389-395. PubMed ID: 37002181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
    McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
    Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of postoperative adjuvant therapy in resected invasive intraductal papillary mucinous neoplasm of the pancreas: A multicenter external validation.
    Choi M; Chong JU; Hwang HK; Seo HI; Yang K; Ryu JH; Roh Y; Kim DH; Lee JH; Lee WJ; Choi SH; Kang CM
    J Hepatobiliary Pancreat Sci; 2021 Aug; 28(8):671-679. PubMed ID: 34028187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcinoma.
    Yopp AC; Katabi N; Janakos M; Klimstra DS; D'Angelica MI; DeMatteo RP; Fong Y; Brennan MF; Jarnagin WR; Allen PJ
    Ann Surg; 2011 May; 253(5):968-74. PubMed ID: 21422912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous tumor: Different prognostic factors for different overall survival.
    Gavazzi F; Capretti G; Giordano L; Ridolfi C; Spaggiari P; Sollai M; Carrara S; Nappo G; Bozzarelli S; Zerbi A
    Dig Liver Dis; 2022 Jun; 54(6):826-833. PubMed ID: 34219044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the Survival Outcomes of Pancreatic Cancer and Intraductal Papillary Mucinous Neoplasms.
    Yamada S; Fujii T; Hirakawa A; Takami H; Suenaga M; Hayashi M; Niwa Y; Hattori N; Iwata N; Kanda M; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujiwara M; Kodera Y
    Pancreas; 2018 Sep; 47(8):974-979. PubMed ID: 30028445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant chemotherapy for adenocarcinoma arising from intraductal papillary mucinous neoplasia: multicentre ADENO-IPMN study.
    Lucocq J; Hawkyard J; Haugk B; Mownah O; Menon K; Furukawa T; Inoue Y; Hirose Y; Sasahira N; Feretis M; Balakrishnan A; Ceresa C; Davidson B; Pande R; Dasari B; Tanno L; Karavias D; Helliwell J; Young A; Nunes Q; Urbonas T; Silva M; Gordon-Weeks A; Barrie J; Gomez D; Van Laarhoven S; Robertson F; Nawara H; Doyle J; Bhogal R; Harrison E; Roalso M; Ciprani D; Aroori S; Ratnayake B; Koea J; Capurso G; Bellotti R; Stättner S; Alsaoudi T; Bhardwaj N; Rajesh S; Jeffery F; Connor S; Cameron A; Jamieson N; Sheen A; Mittal A; Samra J; Gill A; Roberts K; Søreide K; Pandanaboyana S
    Br J Surg; 2024 Apr; 111(4):. PubMed ID: 38659247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors, Patterns, and Timing of Recurrence Provide Insight into the Disease Biology of Invasive Carcinomas Arising in Association with Intraductal Papillary Mucinous Neoplasms.
    Habib JR; Kinny-Köster B; Amini N; Shoucair S; Cameron JL; Thompson ED; Fishman EK; Hruban RH; Javed AA; He J; Wolfgang CL
    J Gastrointest Surg; 2022 Nov; 26(11):2311-2320. PubMed ID: 35915375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review and meta-analysis comparing the surgical outcomes of invasive intraductal papillary mucinous neoplasms and conventional pancreatic ductal adenocarcinoma.
    Koh YX; Chok AY; Zheng HL; Tan CS; Goh BK
    Ann Surg Oncol; 2014 Aug; 21(8):2782-800. PubMed ID: 24687151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinction of Invasive Carcinoma Derived From Intraductal Papillary Mucinous Neoplasms From Concomitant Ductal Adenocarcinoma of the Pancreas Using Molecular Biomarkers.
    Tamura K; Ohtsuka T; Date K; Fujimoto T; Matsunaga T; Kimura H; Watanabe Y; Miyazaki T; Ohuchida K; Takahata S; Ishigami K; Oda Y; Mizumoto K; Nakamura M; Tanaka M
    Pancreas; 2016 Jul; 45(6):826-35. PubMed ID: 26646266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival and prognosis of invasive intraductal papillary mucinous neoplasms of the pancreas: comparison with pancreatic ductal adenocarcinoma.
    Woo SM; Ryu JK; Lee SH; Yoo JW; Park JK; Kim YT; Yoon YB
    Pancreas; 2008 Jan; 36(1):50-5. PubMed ID: 18192881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic inflammatory changes and oxidative stress in the background of "pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasm".
    Matsuda R; Miyasaka Y; Yamada Y; Kawata J; Sakihama K; Yamamoto T; Saeki K; Yamamoto H; Ohishi Y; Koga Y; Nakamura M; Oda Y
    Virchows Arch; 2020 Dec; 477(6):799-806. PubMed ID: 32468246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.